MP-235

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameMP-235
Drug Alias Nameaurora kinase inhibitors (Montigen)HPK-62MP-235
ClassificationSmall molecules
Mechanisms of ActionAnticancer protein kinase inhibitorsCell cycle inhibitorsSerine/threonine-protein kinase Aurora-A inhibitors +[4] 
TargetsSerine/threonine-protein kinase Aurora-A
Therapy Area/IndicationsPancreatic NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMontigen Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMontigen Pharmaceuticals IncAstex Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsPancreatic NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A